$3.97-0.03 (-0.74%)
KORU Medical Systems, Inc.
KORU Medical Systems, Inc. in the Healthcare sector is trading at $3.97 with a market capitalization of $180M. Wall Street consensus targets $6.80 (5 analysts), implying a +71.3% move over the next 12 months. The stock is currently 40% below its 52-week high of $6.61, remaining 13.3% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $11.76M↑ | $10.90M↑ | $10.40M↑ | $10.19M↑ | $9.64M |
| Gross Profit | $7.23M↑ | $6.82M↑ | $6.26M↓ | $6.48M↑ | $6.05M |
| Operating Income | -$864,923↓ | -$547,104↑ | -$867,679↓ | -$312,655↑ | -$1.25M |
| Net Income | -$807,078↓ | -$486,856↑ | -$777,966↓ | -$206,867↑ | -$1.17M |
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to del...
The United States market has shown robust growth, climbing 3.2% in the last week and up 31% over the past year, with earnings expected to grow annually by 16%. In this context of strong market performance, identifying stocks with solid financial foundations is crucial for investors looking to capitalize on potential gains. While the term "penny stocks" might seem outdated, these often-overlooked smaller or newer companies can offer unique opportunities for growth when supported by strong...
Moby summary of KORU Medical Systems, Inc.'s Q1 2026 earnings call
KORU Medical Systems (NASDAQ:KRMD) reported a “record start to the year” in the first quarter of 2026, posting revenue of $11.8 million, up 22% from the prior-year period, as the company pointed to domestic share gains in subcutaneous immunoglobulin (SCIg), accelerating international growth tied to
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Phreesia (PHR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.